Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Work In Process: 2022-2025

Historic Work In Process for Gyre Therapeutics (GYRE) over the last 2 years, with Sep 2025 value amounting to $4.4 million.

  • Gyre Therapeutics' Work In Process rose 25.36% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 25.36%. This contributed to the annual value of $2.9 million for FY2024, which is 46.67% up from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Work In Process is $4.4 million, which was up 5.32% from $4.2 million recorded in Q2 2025.
  • Gyre Therapeutics' Work In Process' 5-year high stood at $4.4 million during Q3 2025, with a 5-year trough of $2.0 million in Q4 2023.
  • In the last 3 years, Gyre Therapeutics' Work In Process had a median value of $3.2 million in 2024 and averaged $3.2 million.
  • Its Work In Process has fluctuated over the past 5 years, first plummeted by 45.54% in 2023, then surged by 46.67% in 2024.
  • Quarterly analysis of 4 years shows Gyre Therapeutics' Work In Process stood at $3.7 million in 2022, then crashed by 45.54% to $2.0 million in 2023, then soared by 46.67% to $2.9 million in 2024, then rose by 25.36% to $4.4 million in 2025.
  • Its Work In Process stands at $4.4 million for Q3 2025, versus $4.2 million for Q2 2025 and $3.4 million for Q1 2025.